Does Kansas Medicaid Cover Wegovy? KanCare's Weight-Loss Rules for 2026

Yes. KanCare, the Kansas Medicaid program, pays for Wegovy, Zepbound and the Foundayo pill to treat obesity, with prior authorization. Adults qualify at a BMI of 30, or 27 if they also have a condition tied to weight, high blood pressure for example, and all three drugs are preferred on the state’s November 2026 drug list.^[1][2] Separate criteria cover Zepbound for sleep apnea and Wegovy for the liver disease MASH.^[4][5]

Does KanCare cover Wegovy or Zepbound for weight loss?

It does, which sets Kansas apart. Under federal law a state may leave weight-loss drugs out of Medicaid, and most do.^[15] The Kansas criteria instead list Saxenda, Foundayo, Wegovy, Wegovy HD and Zepbound as anti-obesity drugs that need prior authorization, and they cover older drugs such as phentermine and orlistat without one.^[1] Our explainer on why Medicaid treats Ozempic and Wegovy differently covers the federal side.

The request has to show a baseline weight and BMI and a treatment plan that includes diet, activity and behavior changes.^[1] Adults need a BMI of 30 or more, or 27 or more with at least one condition from the state’s list. That list is broad: prediabetes or type 2 diabetes, raised blood pressure or cholesterol, heart disease, fatty liver disease, polycystic ovary syndrome, sleep apnea, osteoarthritis and acid reflux all count.^[1] The prescriber also has to start with a preferred drug unless the patient meets the state’s test for a non-preferred one.^[1]

Saxenda is the exception. It stays on the state’s list of “high-cost” agents, which carries a BMI line of 40 for adults, 3 months of lifestyle changes first, and a one-year wait after a failed drug. The criteria say that section does not apply to Zepbound (since April 1, 2024), Wegovy (since June 1, 2025) or Foundayo (since November 1, 2026).^[1] Foundayo and Wegovy HD needed clinical prior authorization from October 19, 2026, and members already filling one of them at least 80% of the time could get a grandfathered approval.^[7][12]

How has KanCare changed since 2024?

The rules have loosened. In September 2024, a plan summary of the state criteria made Zepbound the preferred drug that adults had to try first, and held Wegovy and Saxenda to a BMI of 40.^[8] Wegovy left that high bar in June 2025, the 7.2 mg Wegovy HD pen became a preferred drug on May 1, 2026, and the November 2026 drug list names Wegovy, Wegovy HD, Zepbound and Foundayo as preferred.^[1][6][2] The Zepbound-first step is gone from the current criteria.

What does a renewal take?

For Zepbound, Wegovy and Foundayo, the first approval lasts 28 weeks. To renew, an adult must have lost 5% of their starting weight by week 12, or 10% by week 28, and kept it off, while staying on the lifestyle plan. A teenager needs a drop of more than 4% in BMI.^[1] The first renewal lasts 6 months and later ones 12 months.^[1] Saxenda is renewed against its own weight-loss table, starting at 3% after 8 weeks for adults.^[1] The dose must stay within the label’s limits, and for Wegovy and Saxenda the patient must be able to reach and hold the full maintenance dose.^[1][13]

Does KanCare cover Wegovy for heart disease?

Yes, through the same anti-obesity criteria. Heart disease is one of the listed conditions, so an adult with a past heart attack or stroke and a BMI of 27 or more meets the weight test.^[1] The old heart route, a BMI from 27 with established heart disease and no diabetes, now sits only in the high-cost section that no longer applies to Wegovy.^[1] Wegovy’s label covers lowering heart risk in adults with heart disease and obesity or overweight.^[13]

What about sleep apnea and MASH?

Both have their own Kansas criteria. Zepbound for sleep apnea needs an adult with moderate to severe apnea confirmed by an in-lab sleep study (polysomnography) at 15 or more events an hour, and a BMI of at least 30.^[4] There is no CPAP requirement. The first approval lasts 12 months, and a renewal needs a 10% weight loss at a year plus a 50% drop in apnea events or a drop of at least 15 an hour.^[4] Someone with type 2 diabetes must use the diabetes form of the drug instead.^[4][14] Our guide to Zepbound for sleep apnea covers the trials.

Wegovy for MASH needs an adult with stage F2 or F3 liver scarring, shown by a biopsy or by a liver stiffness scan in a set range, plus one or more metabolic risk factors, for example central obesity, raised blood pressure or high triglycerides.^[5] Approvals last 12 months, and a renewal needs a measured improvement, which for Wegovy can be a 5% weight loss.^[5] The newer pill Rezdiffra is approved only after 12 months on Wegovy, unless Wegovy cannot be used.^[5] Our page on GLP-1s for MASH covers the evidence.

Can a teenager on KanCare get Wegovy?

Yes, from age 12, once BMI reaches the 95th percentile for a child of that age and sex, the same line the label uses for obesity.^[1][13] Saxenda is also open from 12, but at the higher bar of 140% of the 95th percentile or a BMI of 40.^[1] Zepbound, Foundayo, Wegovy HD and the Wegovy tablets are for adults.^[1] Our page on GLP-1 drugs in teenagers covers the trials in this age group.

What about Ozempic and Mounjaro for diabetes?

People with type 2 diabetes use the diabetes drugs. On the November 2026 list, Ozempic, Trulicity and Victoza are the preferred GLP-1s, and Rybelsus and Bydureon BCise are non-preferred.^[2] Ask your plan how it handles Mounjaro, which we did not find on the list.

How do you file, and how do you appeal a denial?

Most KanCare members are in a managed care plan, and the state form goes to that plan’s prior authorization line. The form lists Healthy Blue of Kansas (fax 877-941-9901), Sunflower (fax 833-645-2740) and UnitedHealthcare (fax 866-940-7328), plus the state’s own line for fee-for-service members (phone 800-933-6593, fax 800-913-2229).^[3]

Plan members first appeal to the plan, within 60 days of the denial notice, and can then ask the state for a fair hearing within the window the federal rules set, at least 90 days after the plan decides.^[10][11] For decisions made by the state agency itself, the Kansas manual requires a written hearing request received within 33 days of the date the notice was mailed, and the Office of Administrative Hearings runs those hearings.^[9] A strong appeal fills the gap the denial names: a missing baseline weight, a condition that was not documented, or a renewal weigh-in. Our walkthrough of prior authorization and appeals covers what to send, and the Kansas state page has the state’s other facts.

What if KanCare will not pay?

If a request is denied and an appeal fails, the cash route remains, though Lilly’s savings card terms exclude government programs such as Medicaid.^[16] In the self-pay prices we track, Novo Nordisk charges $349 a month for most Wegovy pen doses, and Lilly charges $299 for Zepbound at the starting dose, $399 at 5 mg and $449 at 7.5 mg and up when each refill comes within 45 days.^[16][17] Check each program’s terms first. Our comparison of the lowest cash prices for GLP-1s lays out the options.